Nicotinic acid / laropiprant

Key facts

Invented name
Tredaptive
Active substance
Nicotinic acid / laropiprant
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0262/2012
PIP number
Nicotinic acid / laropiprant
Pharmaceutical form(s)
  • Modified-release tablet
  • Age-appropriate dosage form
Condition(s) / indication(s)
  • Treatment of dyslipidaemia
  • Prevention of major vascular and major coronary events
Route(s) of administration
Oral use
Contact for public enquiries
Merck Sharp and Dohme (Europe), Inc.
Belgium
Tel. +33 180464738
E-mail: pip.information@merck.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating